



MYCONIC

CAPITAL CORP.

NEWS RELEASE

MYCONIC CAPITAL ANNOUNCES CLOSING OF MINDSCAPE KETAMINE & INFUSIONS THERAPY ACQUISITION

April 21, 2021 – Vancouver, British Columbia, Canada – Myconic Capital Corp. (formerly, Auralite Investments Inc.) (CSE: MEDI) (FRA: MY0) (the "**Company**" or "**Myconic**") is pleased to announce that, further to its press release of March 10, 2021, it has completed the acquisition of all of the issued and outstanding equity of Mindscape Ketamine & Infusions Therapy, PLLC ("**Mindscape**") a mental health and pain clinic based in Houston, Texas. As a result, Myconic made a cash payment of US\$50,000 and issued 94,292 common shares of Myconic (the "**Payment Shares**") to the sole owner of Mindscape.

The Payment Shares are subject to a lockup period of twelve months, with one third of the Payment Shares each being released at intervals of four, six, and twelve months following closing.

ABOUT MINDSCAPE

Mindscape Ketamine & Infusions Therapy, PLLC is a clinic in Houston, Texas, offering affordable delivery of concierge IV ketamine therapy for treatment-resistant mood disorders, mental health disorders, and chronic pain conditions. Operated by Dr. Quang Henderson, a licensed Board-Certified Emergency Physician with over 20 years of experience with ketamine, Mindscape assists people dealing with depression, anxiety, PTSD, chronic pain, and other mood disorders using the medical procedure of IV ketamine treatments in low dose, high dose, or private sessions.

Mindscape is the only IV ketamine clinic in Houston to offer virtual reality-based guided meditation to complement IV ketamine infusions in the treatment of depression, bipolar disorder, anxiety, PTSD, OCD, and other mood disorders.

ABOUT MYCONIC

Myconic Capital Corp is an investment issuer with a diversified portfolio that is focused on emerging companies active in the high-tech, real estate, cannabis, mining and health & wellness sectors.

On behalf of:

MYCONIC CAPITAL CORP.

"Robert Meister"

Robert Meister
CEO and Director

For further information, please contact:

Robert Meister
Tel: 604-351-6647

The Canadian Securities Exchange (the “CSE”) has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Notice Regarding Forward Looking Information:

This news release contains forward-looking statements including statements regarding any of the Myconic holdings or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and future prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.